Afexa Life Sciences, Inc. Report issue

For profit Phase 1
Founded: Edmonton Canada (1992)
Status: Acquired by Bausch Health Companies (2011)

Organization Overview

First Clinical Trial
2009
NCT00966225
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Afexa Life Sciences | Afexa Life Sciences Inc

Active Ingredients

Drugs in Phase 1 Trials (6)

afx-2 (1 trial)

cellulose (1 trial)

coptis chinesis (1 trial)

glu-xx (1 trial)

ilex kudingcha (1 trial)

stearic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glucose Intolerance (Phase 1)

Hypercholesterolemia (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 6